Inovio Pharmaceuticals, Inc.
13 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as VGX Pharmaceuticals, LLC (to 2013)
18
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 19 to 21, 2026 · next Nov 19
- 1 fee due Dec 27, 2026The maintenance fee for Method and device for minimally invasive in vivo transfection of adipose tissue using electroporation (US 11,684,777) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
- 3 fees due Feb 13 to 18, 2027 · next Feb 13
- 2 fees due Mar 3 to 5, 2027 · next Mar 3
- 4 fees due Apr 13 to 30, 2027 · next Apr 13
- 2 fees due Jun 19 to 26, 2027 · next Jun 19
- 2 fees due Jul 9 to 30, 2027 · next Jul 9
- 2 fees due Aug 4 to 13, 2027 · next Aug 4
- 1 fee due Sep 12, 2027The maintenance fee for DNA antibody constructs encoding anti-ZIKV envelope antibodies (US 11,925,685) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 1 fee due Oct 7, 2027The maintenance fee for Variable current density single needle electroporation system and method (US 10,610,684) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
- 2 fees due Nov 14, 2027
Recent changes
- 3 terms have ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,369,359 | Device and method for single-needle in vivo electroporation In force · From the USPTO record | In force | From the USPTO record | |
| US 7,547,293 | Triggering mechanism for needle-free injector In force · From the USPTO record | In force | From the USPTO record | |
| US 8,563,302 | Optimized high yield synthetic plasmids In force · From the USPTO record | In force | From the USPTO record | |
| US 8,058,253 | Growth hormone releasing hormone treatment to decrease cholesterol levels In force · From the USPTO record | In force | From the USPTO record | |
| US 7,846,720 | Optimized high yield synthetic plasmids In force · From the USPTO record | In force | From the USPTO record | |
| US 9,156,890 | HCV Vaccines and Methods for Using the Same In force · High confidence | In force | High confidence | |
| US 9,156,891 | Vaccines And Methods For Using The Same In force · High confidence | In force | High confidence | |
| US 7,717,874 | Needle-Free Injection System In force · High confidence | In force | High confidence | |
| US 8,617,099 | Injection device plunger auto-disable In force · From the USPTO record | In force | From the USPTO record | |
| US 10,376,692 | Electroporation device and injection apparatus In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 89: 13 patents in force now held by others · 10 lapsed for an unpaid fee · 48 ended at full term · 1 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
36 pending · 13 abandoned · 13 no status recorded